These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24992721)

  • 1. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
    Lian J; Huang XF; Pai N; Deng C
    Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
    Lian J; Huang XF; Pai N; Deng C
    Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.
    Lian J; Huang XF; Pai N; Deng C
    PLoS One; 2014; 9(8):e104160. PubMed ID: 25084453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.
    Liu X; Lian J; Hu CH; Deng C
    Pharmacol Res; 2015 Oct; 100():36-46. PubMed ID: 26218603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
    He M; Zhang Q; Deng C; Wang H; Lian J; Huang XF
    Psychoneuroendocrinology; 2014 Apr; 42():153-64. PubMed ID: 24636512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
    Deng C; Lian J; Pai N; Huang XF
    J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways.
    Lian J; De Santis M; He M; Deng C
    Pharmacol Res; 2015; 95-96():20-6. PubMed ID: 25782398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
    Poyurovsky M; Pashinian A; Levi A; Weizman R; Weizman A
    Int Clin Psychopharmacol; 2005 Mar; 20(2):101-3. PubMed ID: 15729086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice.
    Chen X; Yu Y; Zheng P; Jin T; He M; Zheng M; Song X; Jones A; Huang XF
    Psychoneuroendocrinology; 2020 Apr; 114():104594. PubMed ID: 32007669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity.
    He M; Zhang Q; Deng C; Jin T; Song X; Wang H; Huang XF
    Psychoneuroendocrinology; 2017 Nov; 85():190-199. PubMed ID: 28886461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
    He M; Zhang Q; Deng C; Wang H; Huang XF
    Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Betahistine decreases olanzapine-induced weight gain and somnolence in humans.
    Barak N; Beck Y; Albeck JH
    J Psychopharmacol; 2016 Mar; 30(3):237-41. PubMed ID: 26839321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
    Weston-Green K; Huang XF; Deng C
    PLoS One; 2012; 7(3):e33548. PubMed ID: 22438946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D₂ but not 5-HT2A/2C bindings in rat brains.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():75-80. PubMed ID: 25149912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.
    Fernø J; Varela L; Skrede S; Vázquez MJ; Nogueiras R; Diéguez C; Vidal-Puig A; Steen VM; López M
    PLoS One; 2011; 6(6):e20571. PubMed ID: 21695181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
    Barak N; Beck Y; Albeck JH
    J Clin Psychopharmacol; 2016 Jun; 36(3):253-6. PubMed ID: 27028981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.